VIDEO: TRANSFORM-1, MANIFEST-2 herald ‘exciting time’ for myelofibrosis patients
Click Here to Manage Email Alerts
In this video, Lindsay A.M. Rein, MD, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.
Rein, a hematologic oncologist at Duke Health, discussed the results and implications of two of the major myeloproliferative neoplasms studies presented at ASH – TRANSFORM-1 examined ruxolitinib plus navitoclax versus placebo, while MANIFEST-2 examined ruxolitinib plus pelabresib versus placebo.
“There does seem to be reductions in symptoms which I think is incredible, and I think this is important as we move forward within this exciting time for patients with myelofibrosis and consider combination strategies,” Rein said.
Collapse
Read more about
Click Here to Manage Email Alerts